Literature DB >> 11148005

Treatment of giardiasis.

T B Gardner1, D R Hill.   

Abstract

Giardia lamblia is both the most common intestinal parasite in the United States and a frequent cause of diarrheal illness throughout the world. In spite of its recognition as an important human pathogen, there have been relatively few agents used in therapy. This paper discusses each class of drugs used in treatment, along with their mechanism of action, in vitro and clinical efficacy, and side effects and contraindications. Recommendations are made for the preferred treatment in different clinical situations. The greatest clinical experience is with the nitroimidazole drugs, i.e., metronidazole, tinidazole, and ornidazole, which are highly effective. A 5- to 7-day course of metronidazole can be expected to cure over 90% of individuals, and a single dose of tinidazole or ornidazole will cure a similar number. Quinacrine, which is no longer produced in the United States, has excellent efficacy but may be poorly tolerated, especially in children. Furazolidone is an effective alternative but must be administered four times a day for 7 to 10 days. Paromomycin may be used during early pregnancy, because it is not systematically absorbed, but it is not always effective. Patients who have resistant infection can usually be cured by a prolonged course of treatment with a combination of a nitroimidazole with quinacrine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148005      PMCID: PMC88965          DOI: 10.1128/CMR.14.1.114-128.2001

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  228 in total

1.  Mebendazole and metronidazole in giardial infections.

Authors:  J Gascón; R Abós; M E Valls; M Corachán
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Sep-Oct       Impact factor: 2.184

Review 2.  Albendazole.

Authors:  P Venkatesan
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

3.  Quinacrine-resistant Giardia duodenalis.

Authors:  J A Upcroft; R W Campbell; P Upcroft
Journal:  Parasitology       Date:  1996-03       Impact factor: 3.234

Review 4.  Giardiasis.

Authors:  M S Wolfe
Journal:  Pediatr Clin North Am       Date:  1979-05       Impact factor: 3.278

5.  Comparison of four dosage schedules in the treatment of giardiasis with metronidazole.

Authors:  L Jokipii; A M Jokipii
Journal:  Infection       Date:  1978       Impact factor: 3.553

6.  Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin.

Authors:  J Upcroft; R Mitchell; N Chen; P Upcroft
Journal:  Microb Drug Resist       Date:  1996       Impact factor: 3.431

7.  Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum.

Authors:  D R Hill; J J Burge; R D Pearson
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

8.  Transmission of Giardia lamblia from a day care center to the community.

Authors:  M A Polis; C U Tuazon; D W Alling; E Talmanis
Journal:  Am J Public Health       Date:  1986-09       Impact factor: 9.308

9.  Safety of metronidazole in pregnancy: a meta-analysis.

Authors:  P Burtin; A Taddio; O Ariburnu; T R Einarson; G Koren
Journal:  Am J Obstet Gynecol       Date:  1995-02       Impact factor: 8.661

10.  Outbreak of giardiasis: effect of a new antiflagellate drug, tinidazole.

Authors:  T Andersson; J Forssell; G Sterner
Journal:  Br Med J       Date:  1972-05-20
View more
  139 in total

1.  Antibiotics for Travelers: What's Good and What's Not.

Authors:  Kathryn N. Suh; Jay S. Keystone
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Management of the returning traveler with diarrhea.

Authors:  Philippe P H de Saussure
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

3.  Quinacrine induced mood disturbance--the unmasking of bipolar affective disorder.

Authors:  John Lally; Fintan Byrne; Elizabeth Walsh
Journal:  BMJ Case Rep       Date:  2012-06-21

4.  Towards a rational strategy for monitoring of microbiological quality of ambient waters.

Authors:  Hugo Ramiro Poma; Dolores Gutiérrez Cacciabue; Beatriz Garcé; Elio Emilio Gonzo; Verónica Beatriz Rajal
Journal:  Sci Total Environ       Date:  2012-07-06       Impact factor: 7.963

5.  Susceptibility of Giardia lamblia to Hovenia dulcis extracts.

Authors:  A P R Gadelha; F Vidal; T M Castro; C S Lopes; N Albarello; M G P Coelho; S F L Figueiredo; L H Monteiro-Leal
Journal:  Parasitol Res       Date:  2005-09-07       Impact factor: 2.289

6.  Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex.

Authors:  Toshiaki Shimizu; Haruaki Tomioka
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

7.  Potential Therapeutic Effects of Mepacrine against Clostridium perfringens Enterotoxin in a Mouse Model of Enterotoxemia.

Authors:  Mauricio A Navarro; Archana Shrestha; John C Freedman; Juliann Beingesser; Bruce A McClane; Francisco A Uzal
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

8.  The principal conductance in Giardia lamblia trophozoites possesses functional properties similar to the mammalian ClC-2 current.

Authors:  Eloy G Moreno-Galindo; Julio C Rodríguez-Elías; Mario A Ramírez-Herrera; José A Sánchez-Chapula; Ricardo A Navarro-Polanco
Journal:  Pflugers Arch       Date:  2013-09-17       Impact factor: 3.657

9.  Impact of zooplankton grazing on the excystation, viability, and infectivity of the protozoan pathogens Cryptosporidium parvum and Giardia lamblia.

Authors:  S J Connelly; E A Wolyniak; K L Dieter; C E Williamson; K L Jellison
Journal:  Appl Environ Microbiol       Date:  2007-09-14       Impact factor: 4.792

10.  Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.

Authors:  Roberto Canete; Angel A Escobedo; Maria E Gonzalez; Pedro Almirall
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.